Skip to main content

Table 1 Case series of infants treated with paracetamol for patent ductus arteriosus (PDA)

From: Efficacy and safety of intravenous paracetamol in comparison to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: study protocol for a randomized control trial

Author Year

Number of patients

GA (weeks)

BW (g)

Postnatal age (days)

Daily dosage/administration route

No. of PDA closure

Safety issues

Hammerman 2012 [13]

5

26–32

720–1210

3–35

60 mg/kg oral

5/5

No toxicity observed.

Oncel 2013 [14]

8

27–34

630–2970

5–27

60 mg/kg oral

7/8

Pre-treatment and post-treatment liver enzymes were normal in all patients.

Oncel 2013 [15]

10

24–30

590–990

2–15

60 mg/kg intravenous

10/10

No adverse effects were observed. Pre-treatment and post-treatment liver enzymes were normal in all patients.

Yurttutan 2013 [16]

6

26–33

920–1600

3–7

60 mg/kg oral

5/6

No adverse side effects were observed. Pre-treatment and post-treatment liver enzymes and bilirubin were normal in all patients.

Ozdemir 2013 [17]

7

23–32

620–1615

20–47

60 mg/kg oral

5/7

No side effects, no hepatotoxicity, and no abnormalities in the hematologic and biochemical analyses.

Sinha 2013 [18]

10

27–33

800–1380

4–7

45 mg/kg oral

10/10

No side effects related to paracetamol.

Jasani 2013 [19]

6

28–31

1040–1235

2–8

60 mg/kg oral

6/6

No adverse effects. Pre-treatment and post-treatment liver enzymes were normal in all neonates.

Kessel 2014 [20]

7

26–30

789–1322

not available

60 mg/kg oral

7/7

No side effects related to paracetamol.

Terrin 2014 [21]

8

24–28

551–897

38–94 h

60 mg/kg intravenous

6/8

No side effects related to paracetamol.

Nadir 2014 [22]

7

24–27

656–951

2–22

60 mg/kg oral

5/7

No abnormalities in hematologic and biochemical analyses.